Rybelsus® Tablets (Semaglutide) – 3 mg | 7 mg | 14 mg

Rybelsus® Tablets contain Semaglutide, an oral GLP-1 receptor agonist indicated for the management of type 2 diabetes mellitus. It is the first and only oral GLP-1 therapy designed to help improve glycemic control while also supporting weight management in overweight or obese patients.

Rybelsus works by stimulating glucose-dependent insulin secretion, reducing glucagon levels, slowing gastric emptying, and helping regulate appetite. It is commonly prescribed for patients who prefer an oral alternative to injectable GLP-1 therapies.

Available strengths include 3 mg, 7 mg, and 14 mg, allowing dose escalation based on individual treatment needs.

Medicina Overseas supplies Rybelsus® Tablets for global markets, supporting pharmacies, hospitals, distributors, and bulk importers with export-ready sourcing and reliable supply.

⚠️ Prescription-only medicine. To be used under medical supervision.

✅ KEY BENEFITS (HELPS CONVERSION)

• Oral GLP-1 therapy (no injections)

• Helps control blood sugar levels

• Supports weight management

• Once-daily tablet

• Trusted global brand by Novo Nordisk